You are currently visiting in a browser which is not supported. This may reduce the functionality of the website. For the best experience, please upgrade your browser, or switch to a supported browser. For a list of supported browsers visit:

Hyalomatrix Wound Device Revolutionizing Tissue Regeneration and Advancing Patient Care


Over 125 new healthcare facilities in the U.S. adopt Hyalomatrix

Mundelein, Ill., Sept. 30, 2016

Medline has surged in recent years from participant to powerhouse in the advanced wound care segment, and its dedication to innovative, forward-thinking solutions continues to tackle some of the industry’s toughest problems. Hyalomatrix, Medline’s hyaluronic acid-based wound device, embodies the company’s new approach to deliver unique, highly efficacious products for both chronic wounds and significant burn wounds. The clinical community has clearly taken note, with more than 125 new facilities in 2016 adopting Hyalomatrix into their practice.

With a wide variety of indications including diabetic ulcers, venous ulcers, pressure ulcers, surgical wounds and trauma wounds, Hyalomatrix is the only skin substitute that is not derived from human or animal tissue. Instead, the hyaluronic acid (HA) that comprises Hyalomatrix is created in the same way some of the most sophisticated biologic drugs are manufactured – a process called recombinant DNA technology. The genetic code for HA is programmed into a bacterial cell, and the bacteria then produce HA in a controlled environment.

“HA has been harvested from rooster combs for decades, but recombinant DNA technology allows an incredibly large molecule like HA to be manufactured without animal sources,” says AJ Ford, MSc, MEM, and senior product manager of Medline’s advanced wound care and tissue regeneration portfolio.

Hyaluronic acid represents a new paradigm amongst skin substitute modalities, which classically rely upon collagen, living cell, and/or growth factor components for facilitating healing. When current skin substitute products fail – not unlike using different classes of antibiotics to fight infections – hyaluronic acid’s unique mechanisms of action can offer hope to both patients and providers that struggle with difficult-to-heal wounds and burns.

Additionally, with reimbursement playing a key role in reducing costs and improving high-quality patient care, Hyalomatrix is now eligible for reimbursement as a skin substitute through the Centers for Medicare and Medicaid Services (CMS) in 47 states.

Visit for more information on the Hyalomatrix.

About Medline

Medline is a global manufacturer and distributor serving the healthcare industry with medical supplies and clinical solutions that help customers achieve both clinical and financial success. Headquartered in Mundelein, Ill., the company offers 350,000+ medical devices and support services through more than 1,200 direct sales representatives who are dedicated points of contact for customers across the continuum of care. For more information on Medline, go to or to connect with Medline on its social media channels.

2018-06-05T15:25:23+00:00 Newsroom|